Cantor Fitzgerald Starts Veru, Inc. (VERU) at Overweight

Cantor Fitzgerald analyst Brandon Folkes initiates coverage on Veru, Inc. (NASDAQ: VERU) with a Overweight rating and a price target of $6.00.

The analyst comments "VERU has built a pipeline of what we view as compelling assets, which are funded, in part, by the company’s female condom business and now, Preboost, both of which we think have the potential to provide non-dilutive funding for the company to support continued investment in its pipeline. We believe VERU currently has a cash runway into at least fiscal 2021 (September year-end). As VERU has built itself into a prostate cancer company, the market has continued to value it largely on its historical female condom business, with little value ascribed to VERU-111, VERU-100, or Zuclomiphene citrate, which, if any are successful, could generate revenue in excess of $100MM+ each, thus alone justifying our $6 PT."

For an analyst ratings summary and ratings history on Veru, Inc. click here. For more ratings news on Veru, Inc. click here.

Shares of Veru, Inc. closed at $2.13 yesterday.

You May Also Be Interested In

• Deutsche Bank Downgrades Workday (WDAY) to Hold
• BMO Capital Resumes Global Net Lease (GNL), Upgrades to Outperform
• Goldman Sachs Resumes Luxshare Precision (002475:CH) at Buy